Latest Breaking News On - Advanced melanoma - Page 2 : comparemela.com
1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort and 27% in the BRAFV600 wild-type cohort. 2. Treatment-related grade ≥ 3 adverse events occurred in 68% of the BRAF V600 mutation-positive cohort (most common being lipase increased creatine phosphokinase increased) and 53% in the BRAFV600 wild-type cohort (anemia and dermatitis acneiform).
Rating-levelAdvanced-melanomaBrafv600Ici-and-tkiChronic-diseaseOncology